PINWORM INFECTION IN CHILDREN : SYMPTOMS , RISK FACTORS AND RESPONSE TO TWO DOSE DEWORMING

CLINICAL PROFILE AND RISK FACTORS FOR ENTEROBIUS VERMICULARIS INFESTATION AND THE EFFICACY OF TWO DOSE DEWORMING IN CHILDREN - NIL

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/06/111949

Enrollment

394

Registered

2026-06-04

Start date

Unknown

Completion date

Unknown

Last updated

2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B80- Enterobiasis

Interventions

Intervention1: ALBENDAZOLE: ROUTE OF ADMINISTRATION : PER ORAL

DOSE : 200 MG IF AGE LESS THAN 2 YEARS , 400 MG IF AGE MORE THAN 2 YEARS

FREQUENCY : NIGHT TIME DOSE , 1ST DOSE ON DAY 1, 2ND DOSE ON DAY 14 Control Intervention1: NOT APPLICABLE: NOT APPLICABLE

Eligibility

Inclusion criteria

Inclusion criteria: 1. Children aged between 1 to 12 years. 2. Confirmed Enterobius vermicularis infestation via either of the following, a Gross detection of perianal worms b Scotch tape test , at least 2 samples on 2 consecutive days c -Stool examination for infective eggs and adult worms 3. Parental consent and child assent where appropriate.

Exclusion criteria

Exclusion criteria: 1.Previous antihelminthic treatment in the past 3 months. 2.Known hypersensitivity to deworming medications. 3.Children coming between February 10th to April 10th and August 10th to October 10th that is 2 months after the Biannual National deworming day falling on February 10th and august 10th .

Design outcomes

Secondary

Measure	Time frame
SECONDARY: Resolution of clinical symptoms, compliance, reinfection rates (at follow up at 1 month)and adverse events and identification of independant risk factors influencing transmission. Timepoint: Participant recruitment, data collection and intervention and follow-up: 10- 12 months - Data analysis and report writing 2-4 months	—

Primary

Measure	Time frame
PRIMARY : Rate of negative scotch tape test at 4 weeks( Clinical effectiveness ) SECONDARY: Resolution of clinical symptoms, compliance, reinfection rates (at follow up at 1 month)and adverse events and identification of independant risk factors influencing transmission. Timepoint: -Participant recruitment, data collection and intervention and follow-up: 10- 12 months -Data analysis and report writing 2-4 months	—

Measure

Time frame

PRIMARY : Rate of negative scotch tape test at 4 weeks( Clinical effectiveness ) SECONDARY: Resolution of clinical symptoms, compliance, reinfection rates (at follow up at 1 month)and adverse events and identification of independant risk factors influencing transmission. Timepoint: -Participant recruitment, data collection and intervention and follow-up: 10- 12 months -Data analysis and report writing 2-4 months

—

Countries

India

Contacts

Public ContactDR MERCELIN MELINDA KANIKAIRAJ

Chettinad Hospital And Research Institute

paedsalex@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Jun 29, 2026